Global Patent Index - EP 1161430 A2

EP 1161430 A2 2001-12-12 - EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS

Title (en)

EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF AS PHARMACEUTICALS

Title (de)

EPOTHILON-DERIVATE, VERFAHREN ZU DEREN HERSTELLUNG UND IHRE PHARMAZEUTISCHE VERWENDUNG

Title (fr)

DERIVES D'EPOTHILONE, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION PHARMACEUTIQUE

Publication

EP 1161430 A2 (DE)

Application

EP 00920433 A

Priority

  • DE 19907480 A
  • DE 19954229 A
  • EP 0001104 W

Abstract (en)

[origin: WO0047584A2] The invention relates to the novel epothilon derivatives of general formula (I) wherein R<4> is hydrogen, C1-C10 alkyl, aryl, C7-C20 aralkyl, R<5> is hydrogen, C1-C10 alkyl, aryl, C7-C20 aralkyl, R<6>, R<7> are each a hydrogen atom, or together an additional bond or an oxygen atom, R<8> is a methyl group or hydrogen, and simultaneously R<1a> and R<1b> together represent a trimethylene group and X is a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl residue or simultaneously R<1a> and R<1b> together represent a trimethylene group, R<2> is a methyl, ethyl or propyl group and X is a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl residue or simultaneously R<1a> and R<1b> each represents a methyl group, R<2> is a methyl, ethyl or propyl residue and X is a 2-pyridyl, 2-methyl-4-thiazolyl or 2-methyl-4-oxazolyl residue, wherein the nitrogen and/or sulfur atom in X can be present in oxidized form and, if R<2> and R<8> each means a methyl residue, X can only be a 2-pyridyl residue which is optionally oxidized at the nitrogen atom, including all possible stereoisomers and their mixtures. The novel compounds are useful for producing medicaments.

IPC 1-7 (main, further and additional classification)

C07D 417/06; A61K 31/425; A61P 35/00; C07D 405/06; C07D 413/06; C07D 493/04

IPC 8 full level (invention and additional information)

A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61K 31/4427 (2006.01); A61P 35/00 (2006.01); C07D 405/06 (2006.01); C07D 413/06 (2006.01); C07D 417/06 (2006.01); C07D 493/04 (2006.01)

CPC (invention and additional information)

C07D 405/06 (2013.01); C07D 413/06 (2013.01); C07D 417/06 (2013.01); C07D 493/04 (2013.01)

Citation (search report)

See references of WO 0047584A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 0047584 A2 20000817; WO 0047584 A3 20001228; AU 4101800 A 20000829; BG 105803 A 20020329; BR 0008206 A 20020219; CA 2360952 A1 20000817; CN 1340053 A 20020313; CZ 20012886 A3 20011114; EA 200100833 A1 20020228; EE 200100422 A 20021216; EP 1161430 A2 20011212; HU 0105330 A2 20020529; IL 144370 D0 20020523; JP 2002536450 A 20021029; KR 20010094763 A 20011101; MX PA01008148 A 20030721; NO 20013900 A 20011011; NO 20013900 D0 20010810; PL 350190 A1 20021118; SK 11452001 A3 20020404; US 2006040990 A1 20060223; US 7001916 B1 20060221; YU 57601 A 20050610

INPADOC legal status


2008-02-13 [18D] APPLICATION DEEMED TO BE WITHDRAWN

- Effective date: 20070823

2007-05-09 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20060515

2007-05-09 [RAP1] TRANSFER OF RIGHTS OF AN APPLICATION

- Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

2007-04-11 [RAP1] TRANSFER OF RIGHTS OF AN APPLICATION

- Owner name: BAYER SCHERING PHARMA AG

2001-12-12 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20010713

2001-12-12 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A2

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2001-12-12 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO:

- Free text: AL;LT PAYMENT 20010713;LV PAYMENT 20010713;MK;RO PAYMENT 20010713;SI PAYMENT 20010713